Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Immunotherapy in patients with metastatic castration-resistant prostate cancer: a meta-analysis of data from 7 phase III studies and 3 phase II studies

Fig. 1

Flowchart and core results of the assessment of the studies identified in the meta-analysis. A Selection process for randomized controlled trials included in the meta-analysis. B Hazard ratio for overall survival in overall population treated with immunotherapy versus placebo shown as forest map. C Hazard ratio for progression free survival in overall population treated with immunotherapy versus placebo shown as forest map. D, E Odds ratio for safety estimation in any grade TRAEs (D) and 3–4 grade TRAEs (E) treated with immunotherapy versus placebo. F A subgroup analysis for PFS was performed in patients with ipilimumab and vaccine respectively. G A subgroup analysis on significant 3–4 grade TRAEs of ICBs and vaccines. H PSA response in ICBs group compared to ICBs plus first-line therapies

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us